Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders.
The recent demonstration that immunotherapeutic approaches may be clinically effective for cancer patients has renewed the interest for this strategy of intervention. In particular, clinical trials using adoptive T-cell therapies disclosed encouraging results, particularly in the context of Epstein-Barr-virus- (EBV-) related tumors. Nevertheless, the rate of complete clinical responses is still limited, thus stimulating the development of more effective therapeutic protocols. Considering the relevance of innate immunity in controlling both infections and cancers, innovative immunotherapeutic approaches should take into account also this compartment to improve clinical efficacy. Evidence accumulated so far indicates that innate immunity effectors, particularly NK cells, can be exploited with therapeutic purposes and new targets have been recently identified. We herein review the complex interactions between EBV and innate immunity and summarize the therapeutic strategies involving both adaptive and innate immune system, in the light of a fruitful integration between these immunotherapeutic modalities for a better control of EBV-driven tumors.
Cancer Bioimmunotherapy Unit CRO-IRCCS, National Cancer Institute, Via F. Gallini 2, 33081 Aviano, Italy.
Debora
D
Martorelli
Elena
E
Muraro
Anna
A
Merlo
Riccardo
R
Turrini
Damiana Antonia
DA
Faè
Antonio
A
Rosato
Riccardo
R
Dolcetti
D056704:Adaptive Immunity; D020031:Epstein-Barr Virus Infections / Q000276:immunology* / Q000628:therapy*; D004854:Herpesvirus 4, Human / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D007113:Immunity, Innate; D007167:Immunotherapy / Q000379:methods*; D008223:Lymphoma / Q000276:immunology / Q000628:therapy / Q000821:virology*; D009303:Nasopharyngeal Neoplasms / Q000276:immunology / Q000628:therapy